Physician profile
Allison Bailey
NPI 1053908970
$2,859.38
in general payments reported to CMS, 2019-2025
25 companies · $840 in 2025
The $840 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $385 · 2022: $491 · 2023: $460 · 2024: $683 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,983.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,266.43 | 2021-2025 | |
| Pfizer INC. | $252.42 | 2021-2025 | |
| Lilly USA, LLC | $251.84 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $248.20 | 2021-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $209.87 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Exact Sciences Corporation | $108.65 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $67.79 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $61.89 | 2023-2024 | Gvoke Hypopen |
| Horizon Therapeutics Plc | $46.40 | 2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $42.15 | 2021-2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $40.94 | 2024-2025 | Fanapt, Hetlioz |
| Biohaven Pharmaceutical Holding Company Ltd. | $34.10 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $22.62 | 2021 | |
| Lundbeck LLC | $21.57 | 2024 | Rexulti |
| Aimmune Therapeutics, INC. | $21.43 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $20.82 | 2024 | Vivitrol |
| Phathom Pharmaceuticals, INC. | $19.71 | 2025 | Voquezna |
| Insulet Corporation | $19.39 | 2024 | Omnipod |
| Actelion Pharmaceuticals US, INC. | $18.13 | 2023 | Uptravi, Opsumit |
| Glaxosmithkline, LLC. | $15.83 | 2025 | Trelegy Ellipta |
| Dexcom, INC. | $15.39 | 2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.70 | 2021 | |
| Amgen INC. | $14.58 | 2021 | |
| Nestle Healthcare Nutrition INC. | $13.16 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.